AstraZeneca PLC (AZN) Valuation
Historical valuation analysis based on 500 data points (2024-08-30 to 2026-08-28)
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% o...
AstraZeneca PLC (AZN) currently trades at a P/E ratio of 49.82 (historical range: 47.55–52.95, median: 50.32), placing it at the 41th percentile — near its historical average, P/S ratio of 8.67 (range: 8.28–9.22, 41th percentile — near its historical average), EV/EBITDA of 38.80 (range: 37.11–41.13, 41th percentile).
AstraZeneca PLC appears undervalued relative to its historical range, with most valuation metrics below their median levels.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/E Ratio | 49.82 | 47.55 | 50.32 | 52.95 | 41th | near its historical average |
| P/S Ratio | 8.67 | 8.28 | 8.76 | 9.22 | 41th | near its historical average |
| EV/EBITDA | 38.80 | 37.11 | 39.18 | 41.13 | 41th | near its historical average |